Three Rivers Pharmaceuticals, a privately held firm based in Pennsylvania, obtained the right to sell Infergen in China, beginning March 31, 2009. Infergen, also known as consensus interferon, is a bio-optimized, selective and potent type 1 interferon alpha indicated for patients with chronic hepatitis C. Financial details of the deal were not disclosed. In December 2007, Three Rivers paid $91.3 million to buy the US and Canadian rights to Infergen from Valeant. Infergen was developed by Amgen and approved by the FDA in 1997. More details...

Stock Symbols: (NYSE: VRX) (NSDQ: AMGN)